Treatment of vaginal candidosis with fluconazole.
In patients with vulvovaginal mycosis systemic treatment is being discussed for eradication of possible fungal reservoirs, therefore, the efficacy and toleration of fluconazole, a triazole-derivative, has been investigated in the course of an open, comparative study. 104 patients with clinical, microscopic and cultural evidence of vaginal mycosis were included, 53 of whom were treated with a single dose of 150 mg of fluconazole and 51 patients daily received local treatment with 50 mg of econazole over a period of 6 days. The results regarding clinical efficacy were comparable for both preparations. At follow-up visits 4 to 10 d and 30 to 45 d post therapy the mycological as well as the subjective cure rates were similar. However, there was a higher mycological cure rate in the rectum of fluconazole patients which was statistically verifiable. This enables the elimination of rectal fungal infection as a source of homologous reinfection.
Herzog
R E
RE
Ansmann
E B
EB
D000935:Antifungal Agents / Q000627:therapeutic use*; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D005260:Female; D015725:Fluconazole; D005500:Follow-Up Studies; D006801:Humans; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; D015725:Fluconazole